Standardizing Preclinical Oncology Through Diversified Xenograft Models

Traditional oncology research relies on a spectrum of models, each serving a distinct phase of drug evaluation. CDX platforms offer the fastest route to initial efficacy data, delivering results in five to seven weeks. Conversely, PDX models prioritize the retention of tumor histology and genomic complexity, making them essential for long-term resistance studies over a 16 to 32-week window. For immuno-oncology, humanized models bypass the limitations of immunodeficient hosts, though the choice between hu-PBMC and hu-CD34 configurations requires balancing immune cell reconstitution against the risks of graft-versus-host disease.

Bridging the gap between laboratory screening and clinical validation, organoid-derived xenografts provide a solution when patient tissue is scarce. However, the utility of these models hinges on rigorous standardization. Frameworks such as PDX-MI, MISHUM, and ARRIVE 2.0 aim to ensure reproducibility across institutions, yet field-wide adoption remains inconsistent. By applying these standardized characterization protocols to its portfolio, Altogen Labs seeks to improve the translational value of preclinical oncology programs, ensuring that data generated from early efficacy tests through IND-enabling safety studies remains robust and comparable.